

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

ANNOUNCEMENT OF 2007 ESTIMATED ANNUAL RESULTS

This announcement is made pursuant to Rule 13.09 of the Listing Rules.

Based on the unaudited management accounts prepared by the Company in accordance with HKFRS, the net profit of the Company and its subsidiaries for the year ended 31 December 2007 is expected to be at least 2.8 times of that for the year ended 31 December 2006.

The financial information of the Company for the year ended 31 December 2007 referred to in this announcement has not been audited by the auditor of the Company, and may be different from the audited financial information. The Board confirmed that the disclosure of the financial information of the Company for the year ended 31 December 2007 referred to in this announcement is made after due and careful enquiry. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited.

The board of the directors (the "Board") of The United Laboratories International Holdings Limited (the "Company") announces the estimated annual results of the Company and its subsidiaries for the year ended 31 December 2007 as follows:

(1) Estimated results for the year ended 31 December 2007

Based on the unaudited management accounts prepared by the Company and its subsidiaries for the year ended 31 December 2007 in accordance with Hong Kong Financial Reporting Standards ("HKFRS"), the estimated net profit for the year ended 31 December 2007 is expected to be at least 2.8 times of that for the year ended 31 December 2006. Detailed financial information of the Company will be published in the forthcoming 2007 annual report of the Company.

The financial information of the Company for the year ended 31 December 2007 referred to in this announcement has not been audited by the auditor of the Company, and may be different

from the audited financial information. The Board confirmed that the disclosure of the financial information of the Company for the year ended 31 December 2007 referred to in this announcement is made after due and careful enquiry. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

(2) Results of last year

The net profit attributable to the equity holders of the Company for the year ended 31 December 2006 was HK\$173.8 million.

The earnings per share of the Company for the year ended 31 December 2006 was HK\$0.19.

The above financial figures were prepared in accordance with HKFRS.

(3) Reason for estimated results increase

The pharmaceutical market has experienced a fast growth in 2007. The increase in net profit for the year ended 31 December 2007 was mainly attributable to the increase in the sales of our intermediate products, bulk medicine and finished products.

By Order of the Board
The United Laboratories
International Holdings Limited
Choy Kam Lok
Chairman

Hong Kong, 20 March 2008

As at the date of this announcement, the Board comprises Mr Choy Kam Lok, Ms Peng Wei and Mr Leung Wing Hon as executive directors; Ms Choy Siu Chit as non-executive director; and Messrs Heng Kwo Seng, Huang Bao Guang and Song Ming as independent non-executive directors.